Articles by Lung Cancers Today Editors
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
The study, which expanded on phase 3 ADAURA, compared treatment with neoadjuvant osimertinib with or without chemotherapy.
Results demonstrated extended median progression-free survival by nearly 9 months versus standard of care.
The updated data showed an overall survival benefit with osimertinib for treating EGFR-mutated NSCLC.
The trial compared the combination with chemotherapy alone in patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Phase 2 of the study investigated the targeted therapy in treatment-naive patients with stage III ALK-positive disease.
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Ivonescimab plus chemotherapy “demonstrated a statistically significant and clinically meaningful improvement” in PFS.
The ALA and its LUNG FORCE initiative are lighting up buildings and landmarks across the nation this week to inspire action.
Dr. Le Marchand’s "seminal work has elucidated racial and ethnic disparities in lung cancer risk," officials said.
Dr. Shaw is being recognized for her "groundbreaking work in defining ALK- and ROS1-positive lung cancers," officials said.
Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in NSCLC.
Rilertinib showed significantly longer progression-free survival compared with gefitinib.
Plinabulin combined with docetaxel showed improved survival in patients with wild-type EGFR NSCLC.
Osimertinib demonstrated a manageable safety profile for the treatment of stage III EGFR-mutated NSCLC.
More than one-third of patients with platinum-resistant ES-SCLC responded to treatment.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.